Delivery Order SPE2DB24D2011-SPE2DB24FBPXT
- Not listed
- This federal contract award is for the delivery of MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract has a ceiling value of $7,365.76 and was awarded to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00...
- This federal contract award from the Defense Logistics Agency (DLA) is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML pharmaceutical products to the government. The contract, valued at $7,553.56, was awarded to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. Amerisourcebergen has a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00, which serves as the...
- This federal contract award is for the delivery of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $1,578.00, was awarded to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025, which...
- This federal contract award is for the delivery of MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The $7,089.53 firm-fixed price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on July 15, 2025, with a completion date of July 16, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award is for the pharmaceutical product Mounjaro 7.5 mg/0.5 ml pen, 0.5 ml, with a ceiling value of $3,748.35 and a performance period ending on July 1, 2024. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. This is a delivery order contract with a firm-fixed-price pricing type. The contract does not have a...
- This federal contract award is for the delivery of MOUNJARO 15 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $4,435.82, was awarded to Amerisourcebergen Drug Corp's Corporate Office Division on May 3, 2024, with a completion date of May 6, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp is a major supplier of pharmaceutical products and medical supplies to the...
- This federal contract award is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The contract is a Delivery Order with a Firm Fixed Price of $3,945.00 and has an Ultimate Completion Date of April 26, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC)...
- This federal contract award is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The contract has a ceiling value of $1,370.65 and an ultimate completion date of May 8, 2024. The prime contractor is Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, including the Department of Defense (DOD) and Veterans Affairs (VA) healthcare systems. The...
- This federal contract award is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for a ceiling value of $2,176.72. The contract is a delivery order with a firm fixed price, and the ultimate completion date is June 11, 2025. This award is not designated as a set-aside contract, indicating open...
- This federal contract award is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML pharmaceutical products. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract has a ceiling value of $10,355.80 and a completion date of November 15, 2024. It is structured as a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999, which serves as a primary vehicle for providing a...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB24FBPXTDelivery Order
This federal contract award is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML pharmaceutical products, with a ceiling value of $5,215.72. The contract was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of May 30, 2024. It is not designated as a set-aside contract. Amerisourcebergen, through its Corporate Office Division, will leverage its extensive supply chain network to fulfill this order for the DLA, which supports the Department of Defense's (DoD) medical treatment programs and facilities worldwide. Amerisourcebergen also holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, as well as a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 5/29/24 |